Health-related quality of life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide

Disclosures: MD received honoraria from Celgene and Janssen. LM received honoraria from Celgene and Janssen, and received research funding from Celgene, IBMS, and Onyx. CL received honoraria from Celgene and Janssen, and received research funding from Celgene. DTV was a consultant for Celgene and Amgen/Onyx, and received research funding from Millennium/Takeda, GSK, and Acetylon. CZ received honoraria and research funding from Celgene. KS received honoraria from Celgene and Janssen. NJB received honoraria and researching funding from Celgene. SG was a consultant for Celgene. MSM, AEH, and VH are Celgene employees. TF was a consultant for Celgene. J-CE, BA, LC, AF, SL, YE, PG-C, S-SY, MEB, and BL have no conflicts of interest.

Contributions: This study was conceived and designed by Celgene and IFM under supervision by TF; MD, LM, JC-E, BA, LC, AF, SL, YE, DTV, PG-C, SSY, CZ, MEB, BL, KS, NJB recruited patients to the study; SG analyzed the data; all authors interpreted the data; all authors contributed to the writing of the manuscript and gave final approval.